Latest News and Press Releases

SAB BIO Announces Oversubscribed $175 Million Private Placement

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...

DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...

PHOENIX, July 21, 2021 (GLOBE NEWSWIRE) -- Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, today announced The Lymphocyte MAP™, which is the result...

Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR)...